 Shares of Denali Therapeutics Inc. rocketed 29 into record territory in premarket trading Thursday, after Biogen Inc. announced a 465 million equity investment as part of a collaboration on Denalis treatment for Parkinsons disease. Biogens stock was little changed ahead of the open. Under terms of the collaboration, Biogen will make an upfront payment of 560 million, as well as the equity investment from the purchase of 13.3 million newly issued shares, representing about 11 of the shares outstanding, at 34.94 per share, which is 50 above Wednesdays closing price of 23.24. Denali will also be eligible to receive up to 1.125 billion in potential milestone payments depending on the achievement of certain development and commercial milestones. Biogen and Denali will co-develop and co-commercialize Denalis small molecule inhibitors of leucine-rich repeat kinase 2 LRRK2 for Parkinsons, and Biogen will receive exclusive options to license two preclinical programs from Denalis transport vehicle TV technology platform. Denalis stock, which was on track to open above the June 3 record close of 28.82, has rallied 33.4 year to date through Wednesday, while Biogen shares have lost 6.9 and the SP 500 has gained 3.0. 